Clinical Trials
39 trialsCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
SHERLOCK
University Health Network, Toronto
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
iCaRe2
University of Nebraska
DP-04
AstraZeneca
ELEPHAS-02
Elephas
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
TraveraRTGx
Travera Inc
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
SCORE
Natera, Inc.
SPECIAL
University Health Network, Toronto
ELEPHAS-05
Elephas
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
LIBERATE
University Health Network, Toronto
NEUTROFLOW
OncoHost Ltd.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
ORACLE
Guardant Health, Inc.
PARTNER
Azienda Ospedaliera di Padova
Serpentine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
PREFER
Labcorp Corporation of America Holdings, Inc
MOM
Inova Health Care Services
EVIDENT
Sheffield Teaching Hospitals NHS Foundation Trust
MOHCCN-O
University Health Network, Toronto
ROOT
Taproot Health
OCTANE
University Health Network, Toronto
SkinHealth
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
POSITive
European Institute of Oncology
A Follow-up Study of Women Evaluated and Treated for Infertility
National Institutes of Health Clinical Center (CC)
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
G-DEFINER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Repertoire Immune Medicines
PIONEER
SpeciCare
The Incidence of Breast and Other Cancers Among Female Flight Attendants
National Institutes of Health Clinical Center (CC)
EPR Tumor Oximetry With CE India Ink
Dartmouth-Hitchcock Medical Center
N1
CureOne
E3N
Institut National de la Santé Et de la Recherche Médicale, France
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
OHSU Knight Cancer Institute
Assessing the Patient Experience in Cancer Care
Mayo Clinic
TEST
M.D. Anderson Cancer Center